Results 161 to 170 of about 4,810,229 (318)

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Living Well with Living Wills: Application of Protection Motivation Theory to Living Wills Among Older Caucasian and African American Adults. [PDF]

Clin Gerontol, 2009
Allen RS, Phillips LL, Pekmezi D, Crowther MR, Prentice-Dunn S.   +4 more
europepmc   +1 more source

Limitations of 'Living Wills'

, 1995
Finucane, Thomas E.
core  

Alienation and Abstract Labor-Time: Marx and the Romantic Critique. [PDF]

Sci Soc
Isaacs SK.
europepmc   +1 more source

Questions About Living Wills

, 1992
Brew, S. A., Lewis, Joan H., MacDougall, Francis   +2 more
core  

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Re: McCarthy et al: A Practical Guide to Evaluating Artificial Intelligence Imaging Models in Scientific Literature. [PDF]

Ophthalmol Sci
Bair H.
europepmc   +1 more source

Promoting Living Wills

, 1994
Hoepfer, Maureen
core  

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer, Eliza J. McEwin, Zhicheng Wang, Joel Lexchin, Barbara Mintzes   +4 more
wiley   +1 more source

When Routine Care Changes a Life. [PDF]

Ann Fam Med
Bair H.
europepmc   +1 more source